Connect With a Global Community of Oligonucleotide CNS Experts
CNS-targeted oligonucleotide development is entering a critical phase, but progress remains constrained by persistent technical and translational challenges. Drug developers continue to struggle with effective BBB penetration, reliable prediction of human dosing from complex preclinical data, mitigation of long-term neurotoxicity, and the scalable manufacture of increasingly complex conjugated and chemically modified oligonucleotides. As programmes advance, reliance on strategic partnerships has never been greater.
Elevate your brand within the technical conversations shaping outsourcing decisions, as speakers share real-world data on delivery modalities, translational gaps and synthesis constraints.
This is your opportunity to engage with a curated audience, embed your expertise within CNS oligonucleotide pipelines, and position your services as an integral part of development strategies across this rapidly expanding field.
What to Expect?
Meet New CNS Oligonucleotide Partners
Engage with pharma and biotech teams actively advancing CNS oligonucleotide programmes and seeking external partners for BBB delivery, CNS-relevant models, PK/PD translation, safety assessment, and oligonucleotide and conjugate manufacturing.
Showcase Your CNS Oligonucleotide Expertise
Demonstrate your capabilities through targeted speaking, workshop, and exhibition opportunities aligned with core agenda themes, including BBB shuttles, conjugation chemistry, endosomal escape, CNS PK/PD, and manufacturability.
Position Yourself at CNS Oligo Decision Points
Gain focused exposure to senior scientific, translational, and CMC leaders shaping CNS oligonucleotide pipelines in an environment designed for technical discussion rather than broad commercial promotion.
Access Critical Market Intelligence
Gain first-hand insight into emerging CNS oligonucleotide strategies, delivery approaches, safety considerations, and investment priorities through data-driven talks and closed-door discussions.
Key Interest Areas
Our attendees representing the CNS oligonucleotide field are looking for service and solution providers with capabilities in the following areas:
1
CNS Delivery & BBB Shuttle Technologies
Solutions enabling systemic or local CNS delivery, including second-generation BBB shuttles, receptor-mediated transport, and alternative targeting strategies beyond transferrin receptors.
2
Oligonucleotide Conjugation & Chemistry Platforms
Expertise in peptide, lipid, carbohydrate, and antibody conjugation, linker–cargo optimisation, and chemical modification strategies to enhance CNS uptake, stability, and safety.
3
CNS-Relevant In Vivo & Translational Models
Preclinical CNS models including rodent, non-human primate, organoid, and lab-on-chip platforms to assess brain distribution, cellular targeting, efficacy, and neurotoxicity.
4
PK/PD Modelling & Translational Dose Prediction
Advanced PK/PD modelling, biodistribution analysis, and biomarker strategies to translate preclinical CNS exposure and target engagement into confident clinical dosing.
5
Neurotoxicity & Safety De-Risking
Predictive safety assays, CNS-specific toxicity screening, and long-term neurotoxicity evaluation to support IND-enabling and early clinical development.
6
Endosomal Escape & Intracellular Delivery Solutions
Technologies and assays designed to improve cytosolic delivery and overcome intracellular sequestration, maximising functional target engagement in neurons and glial cells.
7
CMC, Scale-Up & GMP Oligonucleotide Manufacturing
Clinical and commercial-scale synthesis of ASOs, siRNAs, aptamers, and complex conjugates, including process development, analytical characterisation, and GMP readiness.
8
Regulatory, IND-Enabling & Clinical Strategy Support
Regulatory guidance, IND-enabling study design, and clinical translation support specific to CNS oligonucleotide therapeutics.
Hear What a Past Sponsor Has to Say
The meeting was very interactive. The balance between the presentation and the roundtable discussion was really good. I learned a lot and made valuable connections as well.
Setsu Endoh- Yamagami, Senior Scientist, FUJIFILM
Testimonial from the 5th Oligonucleotide for CNS US Summit
Audience Composition
Company Type
Attendee Seniority
Attending Companies Include
Available Inventory
We have a range of inventory from standard booth and speaking slots to more bespoke deliverables such as lanyards, exclusive dinners and tours to help elevate your brand.
Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Tazeen Kapadia
Partnerships Director
Maintain Your Competitive Edge
Position your solutions alongside leading partners enabling CNS oligonucleotide delivery, translation, and clinical progression.
Network With CNS Oligos Decision-Makers
Engage with senior scientific and translational leaders driving CNS oligonucleotide programs and actively sourcing external expertise.
Showcase Your CNS Oligos Capabilities
Build a bespoke partnership, from data-driven presentations to targeted exhibition formats, align with the rapidly growing European based field.